The outcome of hepatitis C virus infection after liver transplantation- is it influenced by the type of immunosuppression?

Journal of Hepatology

Volumn 30, Issue 4, 1999, Pages 731-738

  Papatheodoridis, George V ^a   Patch, David ^a   Dusheiko, Geoffrey M ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0033035232     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80208-6     Document Type: Review

References (87)

1. Wright T.L., Donegan E., Hsu H.H., Ferrell L., Lake J.R., Kim M., et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 103:1992;317-322.
2. Sallie R., Cohen A.T., Tibbs C.J., Portmann B.C., Rayner A., O'Grady J.G., et al. Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological study. J Hepatol. 21:1994;536-542.
3. Gane E.J., Portmann B.C., Naoumov N.V., Smith H.M., Underhill J.A., Donaldson P.T., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 334:1996;815-820.
4. Boker K.H.W., Dalley G., Bahr M.J., Mascher H., Tillmann H.L., Trautwein C., et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 25:1997;203-210.
5. Marzano A., Smedile A., Abate M., Ottobrelli A., Brunetto M., Negro F., et al. Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. J Hepatol. 21:1994;961-965.
6. Collier J., Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology. 27:1998;2-6.
7. Chang K-M, Rehermann B., Chisari F.V. Immunopathology of hepatitis C. Springer Semin Immunopathol. 19:1997;57-68.
8. Koziel M.J. Mechanisms of liver injury in hepatitis C infection. Kaplowitz N., Liver Injury Update: Clinical Complications and Mechanistic Role of Cells of the Liver. 1997;131-144 American Association for the Study of Liver Diseases, Postgraduate Course, Chicago.
9. Chisari F.V. Cytotoxic T cells and viral hepatitis. J Clin Invest. 99:1997;1472-1477.
10. Rehermann B., Chang K-M, McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest. 98:1996;1431-1440.
11. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M-C, et al. Possible mechanism involving Tlymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1995;1006-1007.
12. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell mediated immune response. J Clin Invest. 98:1996;706-714.
13. Lechmann M., Ihlenfeldt H.G., Braunschweiger I., Giers G., Jung G., Matz B., et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology. 24:1996;790-795.
14. Farci P., Alter H.J., Govindarajan S., Wong D., Engle R., Lesniewski R.R., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 258:1992;135-140.
15. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci. 91:1994;1294-1298.
16. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci. 91:1994;7792-7796.
17. Shimizu Y.K., Hijikata M., Iwamoto A., Alter H.J., Purcell R.H., Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 68:1994;1494-1500.
18. Farci P., Bukh J., Purcell R.H. The quasispecies of hepatitis C virus and the host immune response. Springer Semin Immunopathol. 19:1997;5-26.
19. Feray C., Gigou M., Samuel D., Ducot B., Maisonneuve P., Reynes M., et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med. 128:1998;810-816.
20. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology. 28:1998;1117-1120.
21. Bjorkander J., Cunningham-Rudles C., Lundin P., Olsson R., Soderstrom R., Hanson L.A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgG subclass deficiency. Am J Med. 84:1988;107-111.
22. Bjoro K., Froland S.S., Yun Z., Samdal H.H., Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin. N Engl J Med. 331:1994;1607-1611.
23. Thomson B.J., Doran M., Lever A.M.L., Webster A.D.B. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet. i:1987;539-541.
24. Liaw Y-F, Lee C-S, Tsai S-L, Liaw B-W, Chen T-C, Sheen I-S, et al. T-cell mediated hepatotoxicity in patients with chronic hepatitis C virus infection. Hepatology. 22:1995;1368-1373.
25. Nelson D.R., Marousis C.G., Davis G.L., Rice C.M., Wong J., Houghton M., et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 158:1997;1473-1481.
26. Honda M., Kaneko S., Sakai A., Unoura M., Murakami S., Kobayashi K. Degree of diversity of hepatitis C virus quacispecies and progression of liver disease. Hepatology. 20:1994;1144-1151.
27. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N., Marumo F., et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 22:1995;30-35.
28. Naito M., Hayashi N., Moribe T., Hagiwara H., Mita E., Kanazawa Y., et al. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology. 22:1995;407-412.
29. Friedman S.L. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 328:1993;1828-1835.
30. Schirren C.A., Jung M-C, Mamin M., Hoffman R.M., Gerlach J.T., Diepolder H.M., et al. Intrahepatic T cells from hepatitis C virus reinfected liver transplants are multispecific and produce gammainterferon. [abstract] Hepatology. 26:(Suppl):1997;153A.
31. Gane E.J., Naoumov N.V., Qian K-P, Mondelli M.U., Maertens G., Portmann B.C., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 110:1996;167-177.
32. Gretch D.R., Bacchi C.E., Corey L., Rosa C.D., Lesniewski R.R., Kowdley K., et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology. 22:1995;1-9.
33. Feray C., Gigou M., Samuel D., Paradis V., Mishiro S., Maertens G., et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 108:1995;1088-1096.
34. Martell M., Esteban J.I., Quer J., Vargas V., Esteban R., Guardia J., et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol. 68:1994;3425-3436.
35. Gretch D.R., Polyak S.J., Wilson J.J., Carithers R.L., Perkins J.D., Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol. 70:1996;7622-7631.
36. Papatheodoridis G.V., Andrew D., Clewley G., Dusheiko G., Davidson B., Rolles K., et al. HCV viremia after liver transplantation for HCV cirrhosis: relation to type of immunosuppression. [abstract] Hepatology. 28:(Suppl):1998;462A.
37. Asanza C.G., Carcia-Monzon C., Clemente G., Salcedo M., Garcia-Buey L., Garcia-Iglesias C., et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology. 26:1997;755-763.
38. Fukumoto T., Berg T., Ku Y., Bechstein W., Knoop M., Lemmens H-P, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology. 24:1996;1351-1354.
39. Feray C., Gigou M., Samuel D., Paradis V., Wilber J., David M.F., et al. The course of hepatitis C virus infection after liver transplantation. Hepatology. 20:1994;1137-1143.
40. Schluger L.K., Sheiner P.A., Thung S.N., Lau J.Y.N., Min A., Wolf D.C., et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology. 23:1996;971-976.
41. Dickson R.C., Caldwell S.H., Ishitani M.B., Lau J.Y.N., Driscoll C.J., Stevenson W.C., et al. Clinical and histological patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 61:1996;701-705.
42. Gordon F.D., Poterucha J.J., Germer J., Zein N.N., Batts K.P., Gross Jr J.B., et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation. 63:1997;1419-1423.
43. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., et al. Interrelationship of blood-transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
44. Takahashi M., Yamada G., Miyamoto R., Doi T., Endo H., Tsuji T. Natural history of chronic hepatitis C. Am J Gastroenterol. 88:1993;240-243.
45. Tong M.J., El-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
46. Hanafusa T., Ichikawa Y., Kishikawa H., Kyo M., Fukunishi T., Kokado Y., et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 66:1998;471-476.
47. Shuhart M.C., Bronner M.P., Gretch D.R., Thomassen L.V., Wartelle C.F., Tateyama H., et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology. 26:1997;1646-1652.
48. Rosen H.R., Gretch D.R., Oehlke M., Flora K.D., Benner K.G., Rabkin J.M., et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation. 65:1998;1178-1182.
49. Zhou S., Terrault N.A., Ferrell L., Hahn J.A., Lau J.Y.N., Simmonds P., et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology. 24:1996;1041-1046.
50. Gayowski T., Singh N., Marino I.R., Vargas H., Wagener M., Wannstedt C., et al. Hepatitis C virus genotypes in liver transplant recipients. Impact on posttransplant recurrence, infections, response to interferon-α therapy and outcome. Transplantation. 64:1997;422-426.
51. Charlton M., Seaberg E., Wiesner R., Everhart J., Zetterman R., Lake J., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 28:1998;823-830.
52. Chazouilleres O., Kim M., Combs C., Ferrell L., Bacchetti P., Roberts J., et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 106:1994;994-999.
53. Crespo J., Carte B., Lozano J.L., Casafont F., Rivero M., de la Cruz F., et al. Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia. Am J Gastroenterol. 92:1997;1458-1482.
54. Magrin S., Craxi A., Fabiano C., Simonetti R.G., Fiorentino G., Marino L., et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology. 19:1994;273-279.
55. Tur-Kaspa R., Burk R.D., Shaul Y., Shafritz D.A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci. 83:1986;1627-1631.
56. Di Martino V., Saurini F., Samuel D., Gigou M., Dussaix E., Reynes M., et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology. 26:1997;1343-1350.
57. Zervos X.A., Weppler D., Fragulidis G.P., Torres M.B., Nery J.R., Khan M.F., et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 65:1998;1044-1046.
58. Wiesner R.H. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group. Transplantation. 66:1998;493-499.
59. Rosen H.R., Shackleton C.R., Higa L., Gralnek I.M., Farmer D.A., McDiarmid S.V., et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 92:1997;1453-1457.
60. Berenguer M., Prieto M., Cordoba J., Rayon J.M., Carrasco D., Olaso V., et al. Early development of chronic active hepatitis in recurrent hepatitis C after liver transplantation: association with treatment of rejection. J Hepatol. 28:1998;756-763.
61. Sheiner P.A., Schwartz M.E., Mor E., Schluger L.K., Theise N., Kishikawa K., et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology. 21:1995;30-34.
62. Papatheodoridis G.V., Dhillon A.P., Davies S., Dusheiko G., Davidson B., Rolles K., et al. Predictive factors of histological outcome in post-transplant HCV infection. [abstract] Hepatology. 28:(Suppl):1998;260A.
63. Vierling J.M. Prevention and treatment of allograft rejection. In: American Association for the Study of Liver Diseases. Postgraduate Course. Liver Injury Update: Clinical Complications and Mechanistic Role of Cells of the Liver. Chicago. 1997;85-93.
64. Morris R.E. New immunosuppressive drugs. Busuttil R.W., Klintmalm G.B., Transplantation of the Liver. 1996;760-796 W.B. Saunders Co. Philadelphia, Pennsylvania.
65. Winklestein A. The effects of azathioprine and 6-MP on immunity. J Immunopharmacol. 1:1979;429-454.
66. Sheiner P.A., Boros P., Klion F.M., Thung S.N., Schluger L.K., Lau J.Y.N., et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 28:1998;831-838.
67. Feray C., Samuel D., Gigou M., Paradis V., David M.F., Lemonnier C., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 22:1995;1084-1089.
68. Wright T.L., Combs C., Kim M., Ferrell L., Bacchetti P., Ascher N., et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology. 20:1994;773-779.
69. Ruggieri A., Harada T., Matsuura Y., Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology. 229:1997;68-76.
70. Frizell E., Abraham A., Doolittle M., Bashey R., Kresina T., Van Thiel D., et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology. 107:1994;492-498.
71. Khanna A., Li B., Sharma V.K., Suthanthiran M. Immunoregulatory and fibrogenetic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-β expression. Transplant Proc. 28:1996;2015-2018.
72. Wolf G., Thaiss F., Stahl R.A. Cyclosporin stimulates expression of transforming growth factor-β in renal cells. Transplantation. 60:1995;237-241.
73. Ahuja S.S., Shrivastav S., Danielpour D., Balow J.E., Boumpas D.T. Regulation of transforming growth factor-β1 and its receptor by cyclosporin in human T-lymphocytes. Transplantation. 60:1995;718-723.
74. Shihab F.S., Bennett W.M., Tanner A.M., Andoh T.F. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation. 64:1997;1829-1837.
75. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
76. Brumage L.K., Wright T.L. Treatment for recurrent viral hepatitis after liver transplantation. J Hepatol. 26:1997;440-445.
77. Cattral M.S., Krajden M., Wanless I.R., Rezig M., Cameron R., Creig P.D., et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation. 61:1996;1483-1488.
78. Gane E.J., Tibbs C.J., Ramage J.K., Portmann B.C., Williams R. Ribavirin therapy for hepatitis C infection following transplantation. Transpl Int. 8:1995;61-64.
79. Bizollon T., Palazzo U., Ducerf C., Chevallier M., Elliott M., Baulieux J., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 26:1997;500-504.
80. McHutchison J.G. Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat? Hepatology. 26:1997;505-506.
81. Fong T.L., Valinluck B., Govindarajan S., Charboneau F., Adkins R.H., Redeker A.G. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 107:1994;196-199.
82. Vento S., Cainelli F., Mirandola F., Cosco L., Di Perri G., Solbiati M., et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 347:1996;92-93.
83. Gruber A., Lunberg L.G., Bjorkholm M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J Intern Med. 234:1993;223-225.
84. Fan F.S., Tzeng C.H., Hsiao K.I., Hu S.T., Liu W.T., Chen P.M. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant. 8:1991;417-420.
85. Singh N., Gayowski T., Wannstedt C.F., Shakil O., Wagener M.M., Fung J.J., et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. A prospective, randomized, controlled trial. Transplantation. 65:1998;82-86.
86. Rolles K., Davidson B., Mistry P., Burroughs A.K. Neoral versus tacrolimus monotherapy in liver transplantation: a single centre randomised prospective trial. [abstract] The International Congress on Immunosuppression. 1997;43 Professional Postgraduate Services, New Jersey.
87. Singh N., Gayowski T., Wagener M.M., Marino I.R. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation. 61:1996;402-406.